Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection

WHITE PLAINS, N.Y., Jan. 15, 2020 /PRNewswire/ -- Acurx Pharmaceuticals, LLC ( " Acurx " or the " Company " ), a privately held, clinical stage biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials